POLYMED - Fundamental Analysis

Last Updated Time : 02 Aug 25, 12:58 am

🩺 Fundamental Stock Analysis: Poly Medicure Ltd (POLYMED) Rating: 4.1

🔍 Financial Snapshot & Quality Metrics

ROE: 16.0% and ROCE: 20.2% — healthy and efficient capital usage, especially for a mid-cap healthcare player.

Debt-to-Equity: 0.07 — low leverage, giving the company flexibility and financial security.

EPS: ₹33.4 and Qtr Profit Growth: 34.3% — strong earnings progression; high-quality growth trajectory.

Dividend Yield: 0.15% — minimal payout, indicating reinvestment focus over income distribution.

🚨 Note: FII and DII have marginally reduced stakes — possibly valuation-driven or linked to broader sector rotation.

💰 Valuation Metrics & Technical Indicators

Metric Value Interpretation

P/E Ratio 59.1 Premium vs. Industry PE of 35.8 — justified if growth sustains

P/B Ratio ~7.24 Signals investor confidence in intangible strength

PEG Ratio 1.74 Acceptable — but watch for growth moderation risks

RSI 28.6 Oversold zone — technical bounce potential

MACD –58.4 Bearish — trend still under pressure

Price vs DMA ₹1,977 vs DMA50/200: ₹2,192 / ₹2,267 Trading below averages — attractive re-entry range

Volume: Slightly above 1-week average — suggesting early signs of accumulation.

🧠 Business Model & Strategic Edge

Focus: Medical devices (infusion therapy, blood management, urology, etc.) — deeply embedded in hospitals, diagnostics, and export markets.

Competitive Advantage

In-house manufacturing with global certifications.

Diverse product mix with strong recurring demand.

Export potential into regulated markets (Europe, US).

📌 Investment Strategy

Suggested Entry Zone: ₹1,850–₹1,950 — in line with technical indicators and support zones near 52-week low (~₹1,788).

Long-Term Holding View

Excellent pick for investors seeking exposure to healthcare + manufacturing.

Monitor for margin stability, export traction, and innovation pipeline.

Offers structural growth — but caution on valuation froth and global demand swings.

Looking to see how POLYMED stacks up against similar med-tech players like Trivitron, Opto Circuits, or international benchmarks? I can whip up a crisp comparison across fundamentals, margins, and valuation cycles. Just say the word.

Edit in a page